Printer Friendly

CLINTEC NUTRITION COMPANY TO BEGIN PHASE II CLINICAL TRIALS WITH ORAL PROCYSTEINE IN HIV POSITIVE PATIENTS

 DEERFIELD, Ill., March 2 /PRNewswire/ -- Clintec Nutrition Company announced today that it will begin Phase II controlled human clinical trials with its oral form Procysteine(R), a precursor to the naturally occurring amino acid L-cysteine. Procysteine stimulates the synthesis of intracellular glutathione which may inhibit the replication of Human Immunodeficiency Virus.
 The following eight hospitals and AIDS clinics will begin the Phase II efficacy study in March: University Hospitals of Cleveland, Case Western Reserve University, Cleveland, Ohio; Roger Williams Hospital, Providence, R.I.; The Johns Hopkins Hospital, Baltimore, Md.; AIDS Community Research Consortium, Redwood City, Calif.; West Paces Medical Center, Atlanta, Ga.; Northwestern University Medical School, Chicago, Ill.; Pacific Oaks Medical Group, Beverly Hills, Calif.; The New York Hospital -- Cornell Medical Center, New York, N.Y.
 Clintec recently completed Phase I pharmacokinetics and toleration studies with oral Procysteine(R). According to Dr. Dennis Goldberg, leader of Clintec Nutrition Company's Procycsteine project, preliminary results from the Phase I trials have been very encouraging. Pharmacokinetics studies demonstrated good oral bioavailability and multi-dose toleration studies were very successful.
 Discussions for additional trials are currently under way with the AIDS Clinical Trials Group (ACTG), the multicenter clinical organization of the National Institute for Allergies and Infectious Diseases (NIAID) Division of AIDS.
 The glutathione stimulating effect of Procysteine was first discovered by Drs. Alton Meister and Joanne Williamson in the Department of Biochemistry, Cornell University Medical College, New York, N.Y. Clintec licensed the exclusive rights and all Procysteine patents from the Cornell Research Foundation Inc. Clintec Nutrition Company has been issued patents and has pending a number of patent applications relating to various clinical indications using the Procycsteine composition.
 Clintec Nutrition Company is a joint venture between Baxter Healthcare Corp. and Nestle S.A Clintec is a worldwide leader in clinical nutrition providing a full line of parenteral and enteral nutrition products.
 -0- 3/2/93
 /CONTACT: Dr. Dennis Goldberg or Elizabeth Whitten, 708-317-3053, both of Clintec/


CO: Clintec Nutrition Co. ST: Illinois IN: MTC SU:

WB -- NY047 -- 1883 03/02/93 10:47 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 2, 1993
Words:341
Previous Article:DUFF & PHELPS AFFIRMS RJR NABISCO, INC.'S 'BBB' SENIOR DEBT RATING
Next Article:DRS INDUSTRIES STATEMENT ON COURT ACTION
Topics:


Related Articles
THE IMMUNE RESPONSE CORP. CONFIRMS SCHEDULE FOR COMPLETION OF PHASE II/III CLINICAL TRIAL IN 1992
CLINTEC NUTRITION RECEIVES FDA CLEARANCE TO TEST ORAL FORM OF ITS PROCYSTEINE COMPOSITION IN CLINICAL TRIALS WITH HIV POSITIVE PATIENTS
FREE RADICAL SCIENCES INC. COMPLETES $6.5 MILLION FINANCING
TRANSCEND THERAPEUTICS COMPLETES $2M PRIVATE FINANCING
TRANSCEND THERAPEUTICS BEGINS PHASE II TRIAL OF PROCYSTEINE(R) FOR THE TREATMENT OF MULTIPLE ORGAN DYSFUNCTION (MOD)
CELL GENESYS BEGINS PHASE II TRIAL OF T CELL GENE THERAPY FOR AIDS
TRANSCEND THERAPEUTICS, INC. INITIATES PILOT CLINICAL TRIAL OF PROCYSTEINE IN AMYOTROPHIC LATERAL SCLEROSIS
BIOCHEM PHARMA'S PRODUCTS, COMPOUNDS AND RESEARCH FEATURED AT 39TH ANNUAL ICAAC.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters